Antioxidant systemic effect of short-term Cerebrolysin® administration

González, María E.; Francis, L.; Castellano, Orlando

doi:10.1007/978-3-7091-6467-9_29

Cited by 19 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, the NO levels and SOD activity were reduced in the schizophrenic patients with Cbl treatment (data unpublished). In agreement with our results, another report suggests that Cbl induces a decrease on the CAT and SOD levels [133].…”

Section: Neurotropic-like Factor In Schizophreniasupporting

confidence: 94%

The Potential of Cerebrolysin in the Treatment of Schizophrenia

Flores¹,

Atzori²

2014

View full text Add to dashboard Cite

Schizophrenia and psychosis are psychiatric condition whose neural mechanisms are yet incompletely known, and for which pharmacological treatment is too often ineffective in a growing clinical cohort. Recently, dendritic morphological changes in arborization and dendritic spine density in limbic regions has been reported in postmortem tissue from schizophrenic patients and in animal models of schizophrenia, suggesting that the use of medication improving synaptogenesis may be beneficial as additional treatment of psychotic patients. Cerebrolysin (Cbl) is a drug available for clinical with active neuropeptides fragments that mimics the action of endogenous neurotrophic factors such as BDNF, GDNF, CNTF and NGF, which improves the integrity of the neuronal circuits as well as cognitive and behavioral performance by exerting a neuroprotective effect and promoting the generation of new functional synapses. Recent work from our laboratory has shown that Cbl ameliorates synaptic and dendritic pathology in animal models of schizophrenia by increasing synaptic density and restoring neuronal cytoarchitecture. This neuroprotective effect improves the integrity of the neuronal circuits and improves cognitive and behavioral performance. Importantly, Cbl treatment seems to be safe when used in combination with neuroleptics such as risperidone. The present article analyzes the potential of Cbl in the treatment of neurodevelopmental disease, and reviews the current literature on the effects of Cbl in in vivo animal models of neurodevelopmental disorders like schizophrenia.

show abstract

Section: Neurotropic-like Factor In Schizophreniasupporting

confidence: 94%

The Potential of Cerebrolysin in the Treatment of Schizophrenia

Flores¹,

Atzori²

2014

View full text Add to dashboard Cite

show abstract

“…In addition, many of beneficial effects of Cbl administration are thought to be related to its ability to mimic the action of neurotrophic factors (Veinbergs et al,2000; Tatebayashi et al,2003; Zhang et al,2010). This neurotrophic action mediated by Cbl has been shown to interfere with excitotoxicity, free radical formation, and inflammatory responses (González et al,1998; Hutter‐Paier et al,1998; Veinbergs et al,2000). In vitro studies have shown that Cbl can counteract the destructive effects of glutamate, resulting in increased neuronal viability (Hutter‐Paier et al,1996,1998; Riley et al,2006).…”

mentioning

confidence: 99%

Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia

Vázquez-Roque

Ramos

Tecuatl

et al. 2011

J of Neuroscience Research

View full text Add to dashboard Cite

Neonatal ventral hippocampal lesion (nVHL) in rats has been widely used as a neurodevelopmental model to mimic schizophrenia-like behaviors. Recently, we reported that nVHLs result in dendritic retraction and spine loss in prefrontal cortex (PFC) pyramidal neurons and medium spiny neurons of the nucleus accumbens (NAcc). Cerebrolysin (Cbl), a neurotrophic peptide mixture, has been reported to ameliorate the synaptic and dendritic pathology in models of aging and neurodevelopmental disorder such as Rett syndrome. This study sought to determine whether Cbl was capable of reducing behavioral and neuronal alterations in nVHL rats. The behavioral analysis included locomotor activity induced by novel environment and amphetamine, social interaction, and sensoriomotor gating. The morphological evaluation included dendritic analysis by using the Golgi-Cox procedure and stereology to quantify the total cell number in PFC and NAcc. Behavioral data show a reduction in the hyperresponsiveness to novel environment- and amphetamine-induced locomotion, with an increase in the total time spent in social interactions and in prepulse inhibition in Cbl-treated nVHL rats. In addition, neuropathological analysis of the limbic regions also showed amelioration of dendritic retraction and spine loss in Cbl-treated nVHL rats. Cbl treatment also ameliorated dendritic pathology and neuronal loss in the PFC and NAcc in nVHL rats. This study demonstrates that Cbl promotes behavioral improvements and recovery of dendritic neuronal damage in postpubertal nVHL rats and suggests that Cbl may have neurotrophic effects in this neurodevelopmental model of schizophrenia. These findings support the possibility that Cbl has beneficial effects in the management of schizophrenia symptoms.

show abstract

“…In nerve cells, glucose changes to sorbitol by aldose reductase enzyme and sorbitol accumulation increases free radicals such as hydroxyl-super oxide and hydrogen peroxide and eventually causes cell damage. Based on this mechanism of injury, different prevention and treatment approaches are under investigation [43,44]. As it was mentioned in the introduction, anti-oxidant property of cerebrolysin is 300 times less compared to vitamin E [26].…”

Section: Discussionmentioning

confidence: 99%

Neuroprotective Effect of Cerebrolysin on Diabetic Neuropathy: A Study on Male Rats

Mohtashami¹

2014

J Diabetes Metab

View full text Add to dashboard Cite

Objective: Diabetes mellitus with 10% prevalence in human population leads to disorders of peripheral nervous system in many affected patients. It causes various polyneuropathies in which nerve conductionvelocity decreases. The aim of this study was to investigate the effect of cerebrolysinon the treatment of neural injuries resulted from hyperglycemia.Method: Diabetes was induced in male rats weighing 250 ± 25 gr by intraperitoneal injection of 65 mg/kg streptozocin (STZ). Six weeks after STZ injection and appearance of neuropathy in diabetic rats, animals were divided into four groups: experimental, vehicle, diabetic and control. The experimental and vehicle groups received respectively single dose of 5 mg/kg day -1 cerebrolysinand saline intraperitoneally for two weeks. At the end, in order to find the efficacy of cerebrolysin, all groups underwent behavioral and electrophysiological tests as well as histological investigation.Results: Metabolic parameters in different groups showed inefficacy of cerebrolysin in the treatment of metabolic disorders of diabetes. However, electrophysiological investigations showed efficacy of cerebrolysin in the treatment of diabetic neuropathy in rats. Moreover, investigation on morphologic structure of sciatic nerve was evident of the return of axon degenerative changes and myelin splitting in nerve fibers in cerebrolysin-received group. The results of behavioral studies showed increase in recovery in cerebrolysin group. Conclusion:According to the results, treatment of diabetic neuropathy with daily injection of 5 mg/kg cerebrolysin for two weeks improves rats' condition. J ou rna l o f D ia be tes & M e ta bolism

show abstract

Antioxidant systemic effect of short-term Cerebrolysin® administration

Cited by 19 publications

References 13 publications

The Potential of Cerebrolysin in the Treatment of Schizophrenia

The Potential of Cerebrolysin in the Treatment of Schizophrenia

Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia

Neuroprotective Effect of Cerebrolysin on Diabetic Neuropathy: A Study on Male Rats

Contact Info

Product

Resources

About